Jazz Pharmaceuticals
Zanidatamab
Breast Cancer
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for Zanidatamab in Breast Cancer are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06695845: Phase 2 trial, sponsor Jazz Pharmaceuticals, drug Zanidatamab. Primary completion date 2026-12-31 (estimated).”